TriSalus Life Sciences (TLSI) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed YD Bio (YDES) over the past year, losing 14.8% versus a loss of 66.1%. YD Bio is the larger company by market cap ($410.1 million vs $254.3 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSI | YDES |
|---|---|---|
| Share price | $4.13 | $5.79 |
| Market cap | $254.30M | $410.11M |
| 1-day change | -2.82% | -1.53% |
| YTD return | -40.83% | -52.50% |
| 1-year return | -14.85% | -66.06% |
| 5-year return | -58.28% | — |
| EPS (TTM) | $-1.22 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.95 | $22.00 |
| 52-week low | $2.20 | $1.70 |
| Distance from 52-week high | -48.05% | -73.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +151.82% | — |
| Average volume | 275.38K | 284.92K |
| Shares outstanding | 61.57M | 70.83M |
| Employees | 102 | 13 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSI has outperformed YDES by 51.2 percentage points over the past year.
- The two companies sit in different sectors: TriSalus Life Sciences in Healthcare and YD Bio in Health Care.
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Healthcare · Medical Devices · 102 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
TLSI vs YDES FAQ
Which is bigger, TriSalus Life Sciences or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $410.11M compared with $254.30M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, TLSI or YDES?
TLSI returned -14.85% over the past 12 months, compared with -66.06% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are TriSalus Life Sciences and YD Bio in the same industry?
No. TriSalus Life Sciences is in the Healthcare sector, while YD Bio is in Health Care.